Clinical Trial

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

Study acronym: REC1TE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to evaluate if colchicine in addition to standard of care improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes. Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for 26 weeks with the possibility of an additional 26 week extension of the intervention period. After the treatment period, there will a 5-year follow-up on all available outcome measures via electronic patient records for those who took part in the extension.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-07-07; most recent amendment 2026-07-10.
Status change: Recruiting → Active, Not Recruiting 2025-03-17
Status change: Not Yet Recruiting → Recruiting 2023-08-18
Trial Details
NCT Number NCT05949281
Lead Sponsor Asger Lund, MD
Collaborators: University of Copenhagen, Juvenile Diabetes Research Foundation
Conditions Type 1 Diabetes, Cardiovascular Diseases, Chronic Inflammation
Enrollment 102 participants
Start Date 2023-08-29
Primary Completion 2031-01-15 (estimated)
Study Completion 2031-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-13